Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57595 | 0.74 | KMT2A (0.46) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL762439 | 0.74 | KMT2A (0.65) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL13836388 | 0.73 | KMT2A (0.48) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL20579726 | 0.72 | KMT2A (0.49) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL8155586 | 0.72 | MAPT (0.46) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL61427 | 0.71 | MAPT (0.48) | KMT2AMAPK1L3MBTL1MEN1TDP1 | |
| SCHEMBL30630970 | 0.71 | NQO2 (0.50) | KMT2AMAPK1L3MBTL1MEN1POLB | |
| SCHEMBL2993237 | 0.71 | KMT2A (0.55) | KMT2AMAPK1L3MBTL1MEN1POLB | |
| SCHEMBL12774647 | 0.71 | POLB (0.56) | KMT2AMAPK1L3MBTL1MEN1POLB | |
| SCHEMBL1820230 | 0.70 | KMT2A (0.46) | KMT2AMAPK1L3MBTL1MEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298056-A1 | SMALL MOLECULE INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298056-A1 | SMALL MOLECULE INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CCR5, CCR1 | KMT2A 4616/4885MAPK1 1216/4885L3MBTL1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.